12.07.11
Pivotal Therapeutics Inc., Woodbridge, Ontario, Canada, launched its lead therapeutic VASCAZEN in North America at the recent American Heart Association (AHA) Scientific Sessions 2011 in Orlando, FL.
The company also presented data from its open label study in which 84% of study participants initially presented with moderate to severe deficiencies in omega 3 fatty acids prior to treatment. Following a six-week treatment period on VASCAZEN there was a rapid increase in study participants' omega 3 levels.
“We are successfully executing our strategy implementing the next generation in cardiovascular health management using medical foods while consistently achieving our corporate milestones,” said Dr. George Jackowski, chief scientific officer and chairman of Pivotal Therapeutics. “We will follow up on the interest expressed in our company during the AHA and sharing the outcomes of our REVEAL Clinical Trials which assesses the effectiveness of VASCAZEN as an aid in the dietary management of omega 3 deficient CHD patients in elevating their EPA and DHA omega 3 fatty acid levels.”
The company also presented data from its open label study in which 84% of study participants initially presented with moderate to severe deficiencies in omega 3 fatty acids prior to treatment. Following a six-week treatment period on VASCAZEN there was a rapid increase in study participants' omega 3 levels.
“We are successfully executing our strategy implementing the next generation in cardiovascular health management using medical foods while consistently achieving our corporate milestones,” said Dr. George Jackowski, chief scientific officer and chairman of Pivotal Therapeutics. “We will follow up on the interest expressed in our company during the AHA and sharing the outcomes of our REVEAL Clinical Trials which assesses the effectiveness of VASCAZEN as an aid in the dietary management of omega 3 deficient CHD patients in elevating their EPA and DHA omega 3 fatty acid levels.”